Plerixafor (Mozobil)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Mobilizes hematopoetic stem cells by inhibiting the CXCR4 chemokine receptor and blocking its cognate ligand, stromal cell-derived factor-1α (SDF-1α). One function of CXCR4 is to anchor stem cells to the marrow matrix via SDF-1α or other adhesion molecules.[1][2]
Route: SC
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in EMA indication

  • 2009-07-30: Initial authorization

History of changes in PMDA indications

  • 2016-12-19: Initial approval for the enhancement of mobilization of hematopoietic stem cells to the peripheral blood for autologous peripheral blood stem cell transplantation.

Also known as

  • Code name: AMD-3100
  • Brand name: Mozobil